person · Reporting owner

SIMMONS DAVID S

Disclosed activity across 4 companies

Tapewire entity: 16752
SEC CIK: 0001508519

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACCENDRA HEALTH INC/VA/OMI · Entity 6858	Director	March 30, 2018	April 02, 2018
Viatris IncVTRS · Entity 3277	Director	September 30, 2026	October 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACCENDRA HEALTH INC/VA/

Report date March 30, 2018 · Filed April 02, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	3,197	Reported balance After 2018-03-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-03-30 · Grant · Acquired 54 · Balance 3,197 F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2: Shares acquired through quarterly dividend reinvestment transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d).

F2: Shares acquired through quarterly dividend reinvestment transaction.

Viatris Inc

Report date September 30, 2026 · Filed October 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	4,479	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 2,117 · Balance 4,479 F1: On September 30, 2026, the reporting person was automatically granted 2,117 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the September 30, 2026 closing price of $17.72 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control.
Dividend Equivalent DSUsSEC Table II · derivative / convertible security	Direct	16.6533	Reported balance Holding disclosure · report date 2026-09-30 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 16.6533 F2: Represents dividend equivalent DSUs that accrued with respect to DSUs previously granted to the reporting person with respect to the election to receive payment of quarterly director fees in the form of DSUs and vest on the same schedule as the underlying DSUs. Amount represents dividend equivalent DSUs that accrued with respect to such DSUs in transactions exempt from Section 16 under Rule 16a-11.

Filing footnotes · ownership attribution and instrument terms

F1: On September 30, 2026, the reporting person was automatically granted 2,117 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the September 30, 2026 closing price of $17.72 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control.

F2: Represents dividend equivalent DSUs that accrued with respect to DSUs previously granted to the reporting person with respect to the election to receive payment of quarterly director fees in the form of DSUs and vest on the same schedule as the underlying DSUs. Amount represents dividend equivalent DSUs that accrued with respect to such DSUs in transactions exempt from Section 16 under Rule 16a-11.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PFIZER INC

Report date May 31, 2012 · Filed June 01, 2012

Section 16 reporting ended · disclosed 2012-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock Units SSPSEC Table II · derivative / convertible security	Direct	11,121	Reported balance After 2012-05-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2012-05-31 · Grant · Acquired 77 · Balance 11,121 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Filing footnotes · ownership attribution and instrument terms

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

PPD, Inc.

Report date December 08, 2021 · Filed December 08, 2021

Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2021-12-08 transaction · row 5 3 source rows · reconciled sequence Row 1 · 2021-12-08 · Disposition to issuer · Disposed 469,999 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Row 4 · 2021-12-08 · Grant · Acquired 300,912 · Balance 300,912 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. Row 5 · 2021-12-08 · Disposition to issuer · Disposed 300,912 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. F7: Following the closing of the Merger, the Reporting Person's employment was terminated and the vesting of unvested equity awards of Buyer will be accelerated pursuant to the terms of the Merger Agreement.
Common StockSEC Table I · non-derivative	IndirectBy Trust	0	Reported balance After 2021-12-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-12-08 · Disposition to issuer · Disposed 120,000 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust	0	Reported balance After 2021-12-08 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-12-08 · Disposition to issuer · Disposed 570,760 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.05 · Expires 2027-05-11	Direct	0	Reported balance After 2021-12-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-12-08 · Disposition to issuer · Disposed 2,318,799 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F4: These options, of which 385,438 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 · Expires 2027-05-11	Direct	2,092,413	Reported balance After 2021-12-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-12-08 · Grant · Acquired 385,441 · Balance 2,092,413 F5: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 · Expires 2027-05-11	Direct	0	Reported balance After 2021-12-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-12-08 · Disposition to issuer · Disposed 2,092,413 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F5: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.22 · Expires 2031-02-11	Direct	0	Reported balance After 2021-12-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-12-08 · Disposition to issuer · Disposed 343,347 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F6: This option, which provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement. F7: Following the closing of the Merger, the Reporting Person's employment was terminated and the vesting of unvested equity awards of Buyer will be accelerated pursuant to the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger.

F4: These options, of which 385,438 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F5: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F6: This option, which provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement.

F7: Following the closing of the Merger, the Reporting Person's employment was terminated and the vesting of unvested equity awards of Buyer will be accelerated pursuant to the terms of the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2026 Filed Oct 2, 2026 22:00 UTC	Viatris Inc VTRS · Entity 3277	GrantDeferred Stock Units · Derivative	2,117	$17.72	$37,513.24	Disclosure SEC source: 0001140361-26-038449 · form4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,479 Underlying: Common Stock · 2,117 shares Expires not disclosed F1 · derivative.exercise_price: On September 30, 2026, the reporting person was automatically granted 2,117 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the September 30, 2026 closing price of $17.72 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control. F1 · derivative.exercise_date: On September 30, 2026, the reporting person was automatically granted 2,117 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the September 30, 2026 closing price of $17.72 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control. F1 · derivative.expiration_date: On September 30, 2026, the reporting person was automatically granted 2,117 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the September 30, 2026 closing price of $17.72 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control. Read SEC document
June 30, 2026 Filed Jul 1, 2026 22:02 UTC	Viatris Inc VTRS · Entity 3277	GrantDeferred Stock Units · Derivative	2,362	$15.88	$37,508.56	Disclosure SEC source: 0001140361-26-027263 · form4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,362 Underlying: Common Stock · 2,362 shares Expires not disclosed F1 · derivative.exercise_price: On June 30, 2026, the reporting person was automatically granted 2,362 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the June 30, 2026 closing price of $15.88 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control. F1 · derivative.exercise_date: On June 30, 2026, the reporting person was automatically granted 2,362 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the June 30, 2026 closing price of $15.88 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control. F1 · derivative.expiration_date: On June 30, 2026, the reporting person was automatically granted 2,362 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the June 30, 2026 closing price of $15.88 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:03 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	15,890	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-008886 · form4.xml · derivative · entry 7 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,890 Underlying: Common Stock · 15,890 shares Expires not disclosed F7 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. F7 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2027. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:03 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionDividend Equivalent Units · Derivative	523.0399	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-008886 · form4.xml · derivative · entry 6 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 523.0399 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on August 11, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. F6 · derivative.expiration_date: Represents dividend equivalent units (DEUs) that accrued with respect to the RSUs previously granted on August 11, 2025 and vested on the same schedule as the underlying RSUs. Amount represents DEUs that accrued with respect to such RSUs in transactions exempt from Section 16 under Rule 16a-11. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:03 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionRestricted Stock Units · Derivative	22,820	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-26-008886 · form4.xml · derivative · entry 5 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,820 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. F5 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris Inc. These RSUs vested in full on March 6, 2026. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:03 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	524	$0.00	$0.00	Disclosure SEC source: 0001140361-26-008886 · form4.xml · nonDerivative · entry 4 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Fractional shares have been rounded up in connection with the settlement described in footnote 6 pursuant to the terms of the restricted stock unit (RSU) award agreement under the Viatris Inc. 2020 Stock Incentive Plan. Read SEC document
March 06, 2026 Filed Mar 10, 2026 23:03 UTC	Viatris Inc VTRS · Entity 3277	Exercise / conversionCommon Stock	22,820	$0.00	$0.00	Disclosure SEC source: 0001140361-26-008886 · form4.xml · nonDerivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 03, 2025 Filed Mar 10, 2026 23:03 UTC	Viatris Inc VTRS · Entity 3277	PurchaseCommon Stock	213	$10.43	$2,220.63	Disclosure SEC source: 0001140361-26-008886 · form4.xml · nonDerivative · entry 2 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trusts Disclosed balance after: 1,183 F1 · kind: These shares were acquired by the reporting person's investment advisors in managed accounts as part of the investment advisors' implementation and continued execution of managed investment strategies to mirror certain index funds involving the securities of multiple issuers. F2 · price: Based on information provided by the investment advisor; additional information, including the price range, if any, is unavailable. F3 · ownership.nature: These shares are held in family trusts for which the reporting person or his spouse serve as trustee: (i) 13 shares in a trust for the benefit of the reporting person for which the reporting person serves as trustee; (ii) 63 shares in a trust for the benefit of the reporting person and his children for which the reporting person serves as trustee; (iii) 522 shares in a trust for the benefit of the reporting person's spouse for which the reporting person's spouse serves as trustee; and (iv) 585 shares in trusts for the benefit of the reporting person's children for which the reporting person's spouse serves as trustee. Read SEC document
August 27, 2025 Filed Mar 10, 2026 23:03 UTC	Viatris Inc VTRS · Entity 3277	PurchaseCommon Stock	286	$10.42	$2,980.98	Disclosure SEC source: 0001140361-26-008886 · form4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trusts Disclosed balance after: 970 F1 · kind: These shares were acquired by the reporting person's investment advisors in managed accounts as part of the investment advisors' implementation and continued execution of managed investment strategies to mirror certain index funds involving the securities of multiple issuers. F2 · price: Based on information provided by the investment advisor; additional information, including the price range, if any, is unavailable. Read SEC document
August 11, 2025 Filed Aug 13, 2025 22:05 UTC	Viatris Inc VTRS · Entity 3277	GrantRestricted Stock Units · Derivative	22,820	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001140361-25-030882 · form4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,820 Underlying: Common Stock · 22,820 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2026. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents the right to receive one share of common stock of Viatris Inc. These RSUs will vest on March 6, 2026. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	343,347	Not disclosed Strike: $37.22	Not disclosed	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · derivative · entry 9 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 343,347 shares Expires 2031-02-11 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F6 · price: This option, which provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement. F7 · price: Following the closing of the Merger, the Reporting Person's employment was terminated and the vesting of unvested equity awards of Buyer will be accelerated pursuant to the terms of the Merger Agreement. F6 · derivative.exercise_date: This option, which provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	2,092,413	$36.91 Strike: $10.59	$77,230,963.83	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · derivative · entry 8 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,092,413 shares Expires 2027-05-11 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F5 · price: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F5 · derivative.exercise_date: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	385,441	$0.00 Strike: $10.59	$0.00	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · derivative · entry 7 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,092,413 Underlying: Common Stock · 385,441 shares Expires 2027-05-11 F5 · kind: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F5 · derivative.exercise_date: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerStock Options (Right to Buy) · Derivative	2,318,799	$32.45 Strike: $15.05	$75,245,027.55	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · derivative · entry 6 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,318,799 shares Expires 2027-05-11 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F4 · price: These options, of which 385,438 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. F4 · derivative.exercise_date: These options, of which 385,438 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	300,912	Not disclosed	Not disclosed	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · nonDerivative · entry 5 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3 · price: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. F7 · price: Following the closing of the Merger, the Reporting Person's employment was terminated and the vesting of unvested equity awards of Buyer will be accelerated pursuant to the terms of the Merger Agreement. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon Stock	300,912	$0.00	$0.00	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · nonDerivative · entry 4 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,912 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3 · kind: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. F3 · shares: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	570,760	$47.50	$27,111,100.00	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · nonDerivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 0 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	120,000	$47.50	$5,700,000.00	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · nonDerivative · entry 2 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Read SEC document
December 08, 2021 Filed Dec 8, 2021 21:37 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerCommon Stock	469,999	$47.50	$22,324,952.50	Disclosure SEC source: 0001437749-21-028104 · rdgdoc.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2 · price: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Read SEC document
May 24, 2021 Filed Jun 17, 2021 20:00 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	200,000	$0.00	$0.00	Disclosure SEC source: 0001628280-21-012456 · wf-form4_162395994711530.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 469,999 F1 · kind: The 200,000 shares gifted by Mr. Simmons were transferred to a charitable foundation established by Mr. Simmons and his wife. Read SEC document
April 14, 2021 Filed Apr 16, 2021 20:19 UTC	PPD, Inc. PPD · Entity 15247	SaleCommon Stock	100,000	$42.00	$4,200,000.00	Disclosure SEC source: 0001628280-21-007113 · wf-form4_161860437576835.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 570,760 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
March 17, 2021 Filed Mar 18, 2021 21:21 UTC	PPD, Inc. PPD · Entity 15247	SaleCommon Stock	22,935	$38.00	$871,530.00	Disclosure SEC source: 0001628280-21-005112 · wf-form4_161610246502130.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 670,760 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document
February 12, 2021 Filed Feb 16, 2021 22:00 UTC	PPD, Inc. PPD · Entity 15247	SaleCommon Stock	77,065	$38.01	$2,929,240.65	Disclosure SEC source: 0000899243-21-006668 · doc4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 693,695 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.04, inclusive. The reporting person undertakes to provide to PPD, Inc. (the "Issuer"), any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
February 11, 2021 Filed Feb 16, 2021 22:00 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	343,347	$0.00 Strike: $37.22	$0.00	Disclosure SEC source: 0000899243-21-006668 · doc4.xml · derivative · entry 5 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,347 Underlying: Common Stock · 343,347 shares Expires 2031-02-11 F5 · derivative.exercise_date: These options to purchase common stock vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
February 11, 2021 Filed Feb 16, 2021 22:00 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	423,982	$0.00 Strike: $10.59	$0.00	Disclosure SEC source: 0000899243-21-006668 · doc4.xml · derivative · entry 4 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,706,972 Underlying: Common Stock · 423,982 shares Expires 2027-05-11 F3 · kind: Represents previously awarded stock options vesting upon the achievement of certain EBITDA vesting conditions for fiscal 2020, which were determined to be earned subject to the receipt by the Issuer of the completed audit of its fiscal 2020 financial statements. F4 · derivative.exercise_date: Represents 710,148 vested stock options and 996,824 unvested stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 385,441 stock options with an exercise price of $10.59 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal year 2021. Read SEC document
December 23, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	120,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006291 · doc5.xml · nonDerivative · entry 7 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 120,000 F1 · kind: Represents certain estate planning and charitable giving transfers by the Reporting Person and his wife. The 30,000 shares gifted by Mr. Simmons were transferred to a charitable foundation established by Mr. Simmons and his wife. Read SEC document
December 23, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	120,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006291 · doc5.xml · nonDerivative · entry 6 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F1 · kind: Represents certain estate planning and charitable giving transfers by the Reporting Person and his wife. The 30,000 shares gifted by Mr. Simmons were transferred to a charitable foundation established by Mr. Simmons and his wife. Read SEC document
December 23, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	120,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006291 · doc5.xml · nonDerivative · entry 5 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 120,000 F1 · kind: Represents certain estate planning and charitable giving transfers by the Reporting Person and his wife. The 30,000 shares gifted by Mr. Simmons were transferred to a charitable foundation established by Mr. Simmons and his wife. Read SEC document
December 23, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	120,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006291 · doc5.xml · nonDerivative · entry 4 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 669,999 F1 · kind: Represents certain estate planning and charitable giving transfers by the Reporting Person and his wife. The 30,000 shares gifted by Mr. Simmons were transferred to a charitable foundation established by Mr. Simmons and his wife. Read SEC document
December 02, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006291 · doc5.xml · nonDerivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,999 F1 · kind: Represents certain estate planning and charitable giving transfers by the Reporting Person and his wife. The 30,000 shares gifted by Mr. Simmons were transferred to a charitable foundation established by Mr. Simmons and his wife. Read SEC document
December 02, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	167,760	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006291 · doc5.xml · nonDerivative · entry 2 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 770,760 F1 · kind: Represents certain estate planning and charitable giving transfers by the Reporting Person and his wife. The 30,000 shares gifted by Mr. Simmons were transferred to a charitable foundation established by Mr. Simmons and his wife. Read SEC document
December 02, 2020 Filed Feb 12, 2021 21:15 UTC	PPD, Inc. PPD · Entity 15247	GiftCommon Stock	167,760	$0.00	$0.00	Disclosure SEC source: 0000899243-21-006291 · doc5.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 819,999 F1 · kind: Represents certain estate planning and charitable giving transfers by the Reporting Person and his wife. The 30,000 shares gifted by Mr. Simmons were transferred to a charitable foundation established by Mr. Simmons and his wife. Read SEC document
November 10, 2020 Filed Nov 12, 2020 21:02 UTC	PPD, Inc. PPD · Entity 15247	Exercise / conversionStock Option (Right to Buy) · Derivative	30,000	$10.59 Strike: $10.59	$317,700.00	Disclosure SEC source: 0001628280-20-016307 · wf-form4_160521491515594.xml · derivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,282,990 Underlying: Common Stock · 30,000 shares Expires 2027-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Represents vested stock options and 996,824 unvested stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 809,423 stock options with an exercise price of $10.59 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal years 2020-2021. Read SEC document
November 10, 2020 Filed Nov 12, 2020 21:02 UTC	PPD, Inc. PPD · Entity 15247	Exercise / conversionCommon Stock	30,000	$10.59	$317,700.00	Disclosure SEC source: 0001628280-20-016307 · wf-form4_160521491515594.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 987,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 30, 2020 Filed Nov 3, 2020 21:43 UTC	PPD, Inc. PPD · Entity 15247	Exercise / conversionStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $10.59	$0.00	Disclosure SEC source: 0001628280-20-015374 · wf-form4_160443978710354.xml · derivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,312,990 Underlying: Common Stock · 50,000 shares Expires 2027-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: (1)Represents vested stock options and 996,824 unvested stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 809,423 stock options with an exercise price of $10.59 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal years 2020-2021. Read SEC document
October 30, 2020 Filed Nov 3, 2020 21:43 UTC	PPD, Inc. PPD · Entity 15247	Exercise / conversionCommon Stock	50,000	$10.59	$529,500.00	Disclosure SEC source: 0001628280-20-015374 · wf-form4_160443978710354.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 19, 2020 Filed Feb 22, 2020 00:05 UTC	PPD, Inc. PPD · Entity 15247	GrantStock Options (Right to Buy) · Derivative	366,166	$0.00 Strike: $10.59	$0.00	Disclosure SEC source: 0000899243-20-005529 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,990 Underlying: Common Stock · 366,166 shares Expires 2027-05-11 F1 · kind: Represents previously awarded stock options earned upon the achievement of certain EBITDA vesting conditions for fiscal 2019. F2 · derivative.exercise_date: Represents 366,166 vested stock options and 996,824 unvested stock options which are eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders. Does not include an additional 809,423 stock options with an exercise price of $10.59 which are eligible to vest upon the achievement of certain EBITDA-based vesting conditions for fiscal years 2020-2021. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:13 UTC	PPD, Inc. PPD · Entity 15247	PurchaseCommon stock	40,000	$27.00	$1,080,000.00	Disclosure SEC source: 0000899243-20-004243 · doc4.xml · nonDerivative · entry 6 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907,759 F4 · price: Shares were acquired in a directed share program in connection with the Issuer's initial public offering. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:13 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon stock	603,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004243 · doc4.xml · nonDerivative · entry 5 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 603,000 F3 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:13 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerNon-voting common stock	603,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004243 · doc4.xml · nonDerivative · entry 4 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trust Disclosed balance after: 0 F1 · security: Represents an exercise of vested stock options on January 17, 2020. The exercise of these stock options was already reflected on the reporting person's previously filed Form 3. F3 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:13 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon stock	867,759	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004243 · doc4.xml · nonDerivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,759 F3 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. F2 · ownership.direct: Includes shares owned by the David S. Simmons Revocable Trust. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:13 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerNon-voting common stock	867,759	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004243 · doc4.xml · nonDerivative · entry 2 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Represents an exercise of vested stock options on January 17, 2020. The exercise of these stock options was already reflected on the reporting person's previously filed Form 3. F3 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. F2 · ownership.direct: Includes shares owned by the David S. Simmons Revocable Trust. Read SEC document
January 17, 2020 Filed Feb 12, 2020 21:13 UTC	PPD, Inc. PPD · Entity 15247	OtherStock Options (Right to Buy) · Derivative	180,000	$0.00 Strike: $15.05	$0.00	Disclosure SEC source: 0000899243-20-004243 · doc4.xml · derivative · entry 7 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,318,799 Underlying: Non-voting common stock · 180,000 shares Expires 2027-05-11 F5 · derivative.exercise_date: Of these stock options, 1,156,316 stock options are unvested and will vest in equal annual installments on May 11, 2020, May 11, 2021 and May 11, 2022. F1 · derivative.underlying: Represents an exercise of vested stock options on January 17, 2020. The exercise of these stock options was already reflected on the reporting person's previously filed Form 3. Read SEC document
January 17, 2020 Filed Feb 12, 2020 21:13 UTC	PPD, Inc. PPD · Entity 15247	OtherNon-voting common stock	180,000	$15.05	$2,709,000.00	Disclosure SEC source: 0000899243-20-004243 · doc4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 867,759 F1 · security: Represents an exercise of vested stock options on January 17, 2020. The exercise of these stock options was already reflected on the reporting person's previously filed Form 3. F1 · date: Represents an exercise of vested stock options on January 17, 2020. The exercise of these stock options was already reflected on the reporting person's previously filed Form 3. F2 · ownership.direct: Includes shares owned by the David S. Simmons Revocable Trust. Read SEC document
March 30, 2018 Filed Apr 2, 2018 22:24 UTC	ACCENDRA HEALTH INC/VA/ OMI · Entity 6858	GrantPhantom Stock · Derivative	54	$15.09	$814.86	Disclosure SEC source: 0000075252-18-000061 · edgar.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,197 Underlying: Common Stock · 54 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Shares acquired through quarterly dividend reinvestment transaction. F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document
December 29, 2017 Filed Jan 2, 2018 15:52 UTC	ACCENDRA HEALTH INC/VA/ OMI · Entity 6858	GrantPhantom Stock · Derivative	42	$18.88	$792.96	Disclosure SEC source: 0000075252-18-000003 · edgar.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,143 Underlying: Common Stock · 42 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Shares acquired through quarterly dividend reinvestment transaction. F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document
September 29, 2017 Filed Oct 2, 2017 18:40 UTC	ACCENDRA HEALTH INC/VA/ OMI · Entity 6858	GrantPhantom Stock · Derivative	27	$29.20	$788.40	Disclosure SEC source: 0000075252-17-000116 · edgar.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,101 Underlying: Common Stock · 27 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Shares acquired through quarterly dividend reinvestment transaction. F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document
June 30, 2017 Filed Jul 5, 2017 19:28 UTC	ACCENDRA HEALTH INC/VA/ OMI · Entity 6858	GrantCommon Stock	82.354	$32.52	$2,678.07	Disclosure SEC source: 0000075252-17-000100 · edgar.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,721.764 F1 · shares: Shares acquired through quarterly dividend reinvestment transaction. F2 · balance_after: Total reflects shares acquired through dividend reinvestment transactions not previously included in beneficial ownership. Read SEC document
June 30, 2017 Filed Jul 6, 2017 14:18 UTC Amendment	ACCENDRA HEALTH INC/VA/ OMI · Entity 6858	GrantPhantom Stock · Derivative	24	$32.19	$772.56	Disclosure SEC source: 0000075252-17-000103 · edgar.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,074 Underlying: Common Stock · 24 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2 · shares: Shares acquired through quarterly dividend reinvestment transaction. F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document
May 05, 2017 Filed May 8, 2017 20:55 UTC	ACCENDRA HEALTH INC/VA/ OMI · Entity 6858	GrantPhantom Stock · Derivative	3,050	$0.00	$0.00	Disclosure SEC source: 0000075252-17-000080 · edgar.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 Underlying: Common Stock · 3,050 shares Expires not disclosed F1 · derivative.exercise_price: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.exercise_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F1 · derivative.expiration_date: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.